These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24577239)

  • 1. Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
    Raptis V; Georgianos PI; Sarafidis PA; Sioulis A; Makedou K; Makedou A; Grekas DM; Kapoulas S
    Kidney Blood Press Res; 2013; 38(1):72-82. PubMed ID: 24577239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exercise capacity in polycystic kidney disease.
    Reinecke NL; Cunha TM; Heilberg IP; Higa EM; Nishiura JL; Neder JA; Almeida WS; Schor N
    Am J Kidney Dis; 2014 Aug; 64(2):239-46. PubMed ID: 24787761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease.
    Wang D; Strandgaard S; Borresen ML; Luo Z; Connors SG; Yan Q; Wilcox CS
    Am J Kidney Dis; 2008 Feb; 51(2):184-91. PubMed ID: 18215696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction and oxidative stress in polycystic kidney disease.
    Klawitter J; Reed-Gitomer BY; McFann K; Pennington A; Klawitter J; Abebe KZ; Klepacki J; Cadnapaphornchai MA; Brosnahan G; Chonchol M; Christians U; Schrier RW
    Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1198-206. PubMed ID: 25234311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Lampropoulou I; Intzevidou E; Sioulis A; Balaskas E; Sarafidis PA
    Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.
    Kocyigit I; Yilmaz MI; Orscelik O; Sipahioglu MH; Unal A; Eroglu E; Kalay N; Tokgoz B; Axelsson J; Oymak O
    Nephron Clin Pract; 2013; 123(3-4):157-64. PubMed ID: 23887359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Sioulis A; Balaskas E; Zebekakis P; Sarafidis PA
    Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.
    Raptis V; Loutradis C; Boutou AK; Faitatzidou D; Sioulis A; Ferro CJ; Papagianni A; Sarafidis PA
    Cardiorenal Med; 2020; 10(6):440-451. PubMed ID: 33202410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine.
    Yilmaz MI; Saglam M; Caglar K; Cakir E; Sonmez A; Ozgurtas T; Aydin A; Eyileten T; Ozcan O; Acikel C; Tasar M; Genctoy G; Erbil K; Vural A; Zoccali C
    Am J Kidney Dis; 2006 Jan; 47(1):42-50. PubMed ID: 16377384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide dysregulation in patients with heart failure: the association of depressive symptoms with L-arginine, asymmetric dimethylarginine, symmetric dimethylarginine, and isoprostane.
    Mommersteeg PM; Schoemaker RG; Eisel UL; Garrelds IM; Schalkwijk CG; Kop WJ
    Psychosom Med; 2015 Apr; 77(3):292-302. PubMed ID: 25790241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL; Wang W; Farmer-Bailey H; Gitomer B; Malaczewski M; Klawitter J; Jovanovich A; Chonchol M
    Clin J Am Soc Nephrol; 2018 Oct; 13(10):1493-1501. PubMed ID: 30228110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.
    Eiselt J; Rajdl D; Racek J; Vostrý M; Rulcová K; Wirth J
    Kidney Blood Press Res; 2014; 39(1):50-7. PubMed ID: 24923294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients.
    Morimoto H; Nakao K; Fukuoka K; Sarai A; Yano A; Kihara T; Fukuda S; Wada J; Makino H
    Nephrol Dial Transplant; 2005 Dec; 20(12):2775-82. PubMed ID: 16221689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
    Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammation is linked to low arginine and high ADMA plasma levels resulting in an unfavourable NOS substrate-to-inhibitor ratio: the Hoorn Study.
    van der Zwan LP; Scheffer PG; Dekker JM; Stehouwer CD; Heine RJ; Teerlink T
    Clin Sci (Lond); 2011 Jul; 121(2):71-8. PubMed ID: 21306304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of asymmetric dimethylarginine, nitric oxide, tetrahydrobiopterin, and oxidative stress in patients with acute myocardial infarction by medical treatments.
    Yada T; Kaji S; Akasaka T; Mochizuki S; Ogasawara Y; Tanemoto K; Yoshida K; Kajiya F
    Clin Hemorheol Microcirc; 2007; 37(3):269-76. PubMed ID: 17726257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are increased oxidative stress and asymmetric dimethylarginine levels associated with masked hypertension?
    Inan B; Ates I; Ozkayar N; Kundi H; Topcuoglu C; Dede F; Sennaroglu E
    Clin Exp Hypertens; 2016; 38(3):294-8. PubMed ID: 27018581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.